SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2023 Biotech Charity Contest

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: technetium who wrote (79)3/26/2023 7:57:13 PM
From: technetium3 Recommendations

Recommended By
Aloner
BulbaMan
Lance Bredvold

  Read Replies (1) of 233
 
The turmoil in the banking sector continued for a second week. But still the NASDAQ booked a positive gain of +1.7%, just not as positive as the previous week’s. Biotechs as a category did not fare as well also, with the S&P Biotech composite booking a -3% loss for the week.

The big news this week for individual stocks is INZY up by +83% of its original contest price for the week, apparently due to market pleasing news (like a new CEO) revealed in their 2022 Financial Results report, placing it solidly in second place for YTD return, +243%. First place YTD performer, JSPR, also had a strong gain for the week, third place, up +27%. The big looser was CDTX, down -79% of original price for the week. Though they were able to announce the FDA approval for one of their products, an antifungal to treat candidemia, that good news was apparently overshadowed by their fourth quarter earnings report, with revenue down -45%, disappointing expectations. The slide in DCTX was enough to remove it from 3rd place YTD return last week (+132%) to a still respectable +52% for the year.

The contest portfolios generally were down, the losses in both average and median return for the week of (-$1.9k, -$970), though they still outperformed the S&P Biotech composite. For the YTD the average portfolio is still solidly in the black (+$4.5k), much better than the YTD losses in both the Biotech composites, but far below the NASDAQ’s YTD return of +$13k.

TOMATO’s portfolio posted the best performance for the week, +$6k, primarily from a +$3k return for their 10% position in ETNB, the second place weekly performer. This moved TOMATO into the second place YTD portfolio, ahead of ALONER who dropped -$11k for the week. BLADERUNNER, the first place YTD portfolio also had a losing week, down -$970. But their cushion between their $62k YTD performance and TOMATO has been increased.


Report Time Ranges











From

To

















Recent

3/17/23

3/24/23

















YTD

12/31/2022









Index Portfolios’ Performance









Symbol

Recent P/L

Recent %

YTD P/L

















^IXIC

$1,848.24

1.7%

$12,969.77

















^NBI

$1,192.41

1.3%

-$4,404.55

















^SPSIBI

-$2,863.00

-3.1%

-$11,141.39









Share Performance

Recent Performance

YTD Performance



Top Five



Bottom Five



Top Five



Bottom 5

Symbol

P/L / Initial Price

Symbol

P/L / Initial Price

Symbol

YTD P/L / Initial Price

Symbol

YTD P/L/ Initial Price

INZY

82.9%

CDTX

-79.3%

JSPR

314.1%

ALT

-73.7%

ETNB

30.1%

ALT

-40.7%

INZY

242.9%

BCAB

-71.4%

JSPR

26.9%

VKTX

-31.7%

PRVB

126.0%

AVTX

-64.1%

PACB

16.0%

RBOT

-24.3%

MGTA

99.4%

BLCM

-60.5%

OMER

14.2%

LRMR

-21.5%

EYEN

82.8%

FULC

-56.7%

Average and Median Portfolio Performance



Recent P/L







YTD P/L







Avg.

Median







Avg

Median







-$1,947.91

-$966.88

BLADERUNNER



$4,932.33

$4,464.66

TECHNETIUM

Top Seven Portfolio Performances

Top Recent Performers

Top YTD Performers

Contestant (Prev. Rank)

Recent P/L

P/L vs. ^SPSIBI

YTD P/L (Rank)

Contestant (Prev. Rank)

YTD P/L

vs. Top Portfolio

P/L vs. ^SPSIBI

Rec. P/L (Rank)

1 - TOMATO (5)

$6,026.57

$8,889.57

$25,192.61 (2)

1 - BLADERUNNER (1)

$61,691.93

——

$72,833.33

-$966.88 (8)

2 - A.J. MULLEN (12)

$2,573.16

$5,436.16

-$12,840.42 (13)

2 - TOMATO (3)

$25,192.61

$36,499.33

$36,334.00

$6,026.57 (1)

3 - BULBAMAN (8)

$1,955.21

$4,818.21

-$5,109.48 (11)

3 - ALONER (2)

$24,711.10

$36,980.84

$35,852.49

-$10,963.31 (15)

4 - GENEGURU (10)

$1,601.89

$4,464.88

-$10,674.11 (12)

4 - STEVE LOKNESS (4)

$16,444.96

$45,246.98

$27,586.35

$306.29 (6)

5 - ERIKOTTO (14)

$1,406.94

$4,269.93

-$1,141.76 (9)

5 - ARTHUR RADLEY (5)

$12,318.37

$49,373.56

$23,459.77

-$2,007.24 (9)

6 - STEVE LOKNESS (9)

$306.29

$3,169.29

$16,444.96 (4)

6 - RKRW (7)

$9,634.44

$52,057.49

$20,775.83

$106.10 (7)

7 - RKRW (11)

$106.10

$2,969.10

$9,634.44 (6)

7 - DEW DILIGENCE (6)

$6,504.69

$55,187.25

$17,646.08

-$3,781.73 (11)

Top Portfolios’ Contents

Top Recent Performance Portfolio (TOMATO)

Top YTD Performance Portfolio (BLADERUNNER)

Symbol (Rank)

Current Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

Symbol (Rank)

Initial Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

ETNB

10.0%

10.2% | 27.8%

$2,780.83

$3,008.64

7.8%

CRDF

20.0%

13.4% | 8.6%

$1,714.29

-$3,428.57

4.6%

ETON

10.0%

11.4% | 42.6%

$4,255.32

$425.53

7.0%

CRIS

15.0%

9.2% | -1.3%

-$190.91

$95.45

6.8%

HROW

20.0%

19.9% | 24.8%

$4,959.35

$1,436.31

4.0%

ENTA

5.0%

2.7% | -13.9%

-$693.25

-$217.11

23.2%

OCUL

10.0%

14.0% | 75.1%

$7,508.90

-$142.35

5.7%

IOVA

10.0%

5.4% | -13.5%

-$1,345.85

-$1,455.40

11.6%

PTE

5.0%

3.8% | -3.8%

-$190.81

-$454.13

20.8%

JSPR

20.0%

51.2% | 314.1%

$62,815.73

$5,383.02

1.2%

TARA

15.0%

15.6% | 30.6%

$4,589.55

$111.94

5.1%

MBIO

10.0%

5.5% | -11.5%

-$1,149.37

-$200.00

11.3%

TCON

20.0%

18.0% | 12.8%

$2,550.34

$1,744.97

4.4%

MGTA

5.0%

6.2% | 99.4%

$4,969.62

$237.97

10.0%

TELA

10.0%

7.0% | -12.6%

-$1,260.87

-$104.35

11.4%

MRSN

15.0%

6.5% | -29.5%

-$4,428.33

-$1,382.25

9.5%
















































Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext